Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke
Ann Neurol 88:946-955, Triantafyllou, S.,et al, 2020
Ischemic Stroke and Internal Carotid Artery Web
Stroke 50:e31-e34, Mc Grory, B.,et al, 2019
Three Territory Sign
Neurol Clin Pract 9:124-128, Nouh, A.M.,et al, 2019
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Cryptogenic Stroke
NEJM 374:2065-2074, Saver, J.L., 2016
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Characteristics of Cryptogenic Stroke in Cancer Patients
Ann Clin Trans Neurol 3:280-287, Gon, Y.,et al, 2016
Emerging Risk Factors for Recurrent Vascular Events in Patients with Embolic Stroke of Unertermined Source
Stroke 47:2714-2721, Ueno, Y.,et al, 2016
Risk of Recurrent Neurologic Stroke or Transient Ischemic Attack in Patients with Cryptogenic Stroke and Intrapulmonary Shunt
Echocardiography 33:276-280, Sinha, R.S.,et al, 2015
Lambls Excrescense Associated with Cryptogenic Stroke
Am J Case Rep 16:876-881, Chu, A.,et al, 2015
Recurrent Thromboembolic Events after Ischemic Stroke in Patients with Cancer
Neurol 83:26-33, Navi, B.B.,et al, 2014
Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia
NEJM 371:699-710, DeBaun, M.R.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Practice Parameter: Recurrent Stroke with Patent Foramen Ovale and Atrial Septal Aneurysm
Neurol 62:1042-1050, Messe,S.R.,et al, 2004
Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients with Patent Foramen Ovale
Stroke 35:2145, Homma,S.,et al, 2004
Stroke as the First Manifestation of a Concealed Pancreatic Neoplasia
Rev Neurol 38:332-335, Perez-Lazaro,C.,et al, 2004
Frequency and Mechanisms of Stroke Recurrence After Cryptogenic Stroke
Ann Neurol 54:227-234, Bang,O.Y.,et al, 2003
Cardiac Papillary Fibroelastoma as a Cause of Recurrent Ischemic Strokes: The Diagnostic Value of Serial Transesophageal Echocardiography
Cerebrovasc Dis 14:256-259, Baba, Y.,et al, 2002
Cerebral Infarction in Young Adults
Neurol 50:890-894, Kittner,S.J.,et al, 1998
Surgical Closure of Patent Foramen Ovale in Cryptogenic Stroke Patients
Stroke 28:2376-2381, Homma,S.,et al, 1997